JP2006524058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524058A5 JP2006524058A5 JP2004557582A JP2004557582A JP2006524058A5 JP 2006524058 A5 JP2006524058 A5 JP 2006524058A5 JP 2004557582 A JP2004557582 A JP 2004557582A JP 2004557582 A JP2004557582 A JP 2004557582A JP 2006524058 A5 JP2006524058 A5 JP 2006524058A5
- Authority
- JP
- Japan
- Prior art keywords
- cement
- preparation
- bone
- cement preparation
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004568 cement Substances 0.000 claims description 124
- 238000002360 preparation method Methods 0.000 claims description 87
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 41
- 239000001506 calcium phosphate Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- 210000000988 bone and bone Anatomy 0.000 claims description 35
- 235000011010 calcium phosphates Nutrition 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 34
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 32
- 239000000654 additive Substances 0.000 claims description 30
- 229910052751 metal Inorganic materials 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- 239000002184 metal Substances 0.000 claims description 23
- 239000011777 magnesium Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 230000007547 defect Effects 0.000 claims description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 12
- -1 iodo compound Chemical class 0.000 claims description 12
- 159000000009 barium salts Chemical class 0.000 claims description 11
- 239000000316 bone substitute Substances 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 10
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 10
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 10
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 150000002736 metal compounds Chemical class 0.000 claims description 9
- 235000021317 phosphate Nutrition 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
- 150000002739 metals Chemical class 0.000 claims description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002639 bone cement Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000002902 organometallic compounds Chemical class 0.000 claims description 6
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical group [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 6
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 5
- 150000002484 inorganic compounds Chemical class 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 150000002506 iron compounds Chemical class 0.000 claims description 5
- 229910044991 metal oxide Inorganic materials 0.000 claims description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 5
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
- 150000004706 metal oxides Chemical class 0.000 claims description 4
- 229910052750 molybdenum Inorganic materials 0.000 claims description 4
- 239000011733 molybdenum Substances 0.000 claims description 4
- 229910052758 niobium Inorganic materials 0.000 claims description 4
- 239000010955 niobium Substances 0.000 claims description 4
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 239000010948 rhodium Substances 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- 229910052707 ruthenium Inorganic materials 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229910052715 tantalum Inorganic materials 0.000 claims description 4
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 239000010937 tungsten Substances 0.000 claims description 4
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical group [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 229910052788 barium Inorganic materials 0.000 claims description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 3
- SGUXGJPBTNFBAD-UHFFFAOYSA-L barium iodide Chemical compound [I-].[I-].[Ba+2] SGUXGJPBTNFBAD-UHFFFAOYSA-L 0.000 claims description 3
- 229940075444 barium iodide Drugs 0.000 claims description 3
- 229910001638 barium iodide Inorganic materials 0.000 claims description 3
- 229910021523 barium zirconate Inorganic materials 0.000 claims description 3
- DQBAOWPVHRWLJC-UHFFFAOYSA-N barium(2+);dioxido(oxo)zirconium Chemical compound [Ba+2].[O-][Zr]([O-])=O DQBAOWPVHRWLJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000014413 iron hydroxide Nutrition 0.000 claims description 3
- 235000013980 iron oxide Nutrition 0.000 claims description 3
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 claims description 3
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 159000000008 strontium salts Chemical class 0.000 claims description 3
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 claims description 3
- 229960001025 iohexol Drugs 0.000 claims description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000398 iron phosphate Inorganic materials 0.000 claims description 2
- 150000005527 organic iodine compounds Chemical class 0.000 claims description 2
- 229940065287 selenium compound Drugs 0.000 claims description 2
- 150000003343 selenium compounds Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000004254 Ammonium phosphate Substances 0.000 claims 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims 1
- 235000019289 ammonium phosphates Nutrition 0.000 claims 1
- 229940088623 biologically active substance Drugs 0.000 claims 1
- 229960005423 diatrizoate Drugs 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 229960004108 iobitridol Drugs 0.000 description 7
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical group OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000011837 pasties Nutrition 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 206010010214 Compression fracture Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229910052586 apatite Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000004068 calcium phosphate ceramic Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000001247 metal acetylides Chemical class 0.000 description 2
- 150000004767 nitrides Chemical class 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910021332 silicide Inorganic materials 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910000018 strontium carbonate Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 2
- 239000004135 Bone phosphate Substances 0.000 description 1
- QJDROSDWEPJQDF-UHFFFAOYSA-J C(C=1C(O)=CC=CC1)(=O)[O-].[W+4].C(C=1C(O)=CC=CC1)(=O)[O-].C(C=1C(O)=CC=CC1)(=O)[O-].C(C=1C(O)=CC=CC1)(=O)[O-] Chemical compound C(C=1C(O)=CC=CC1)(=O)[O-].[W+4].C(C=1C(O)=CC=CC1)(=O)[O-].C(C=1C(O)=CC=CC1)(=O)[O-].C(C=1C(O)=CC=CC1)(=O)[O-] QJDROSDWEPJQDF-UHFFFAOYSA-J 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 229910001111 Fine metal Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 1
- ZRIUUUJAJJNDSS-UHFFFAOYSA-N ammonium phosphates Chemical compound [NH4+].[NH4+].[NH4+].[O-]P([O-])([O-])=O ZRIUUUJAJJNDSS-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- DQEPEVJAZOOFDV-UHFFFAOYSA-O azanium;lanthanum;nitrate Chemical compound [NH4+].[La].[O-][N+]([O-])=O DQEPEVJAZOOFDV-UHFFFAOYSA-O 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 235000019347 bone phosphate Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- DLNAGPYXDXKSDK-UHFFFAOYSA-K cerium(3+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ce+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O DLNAGPYXDXKSDK-UHFFFAOYSA-K 0.000 description 1
- VZDYWEUILIUIDF-UHFFFAOYSA-J cerium(4+);disulfate Chemical compound [Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VZDYWEUILIUIDF-UHFFFAOYSA-J 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002251 gadolinium compounds Chemical class 0.000 description 1
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 229960005451 gadoteridol Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229940029407 ioxaglate Drugs 0.000 description 1
- TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical group [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Chemical group O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- JLRJWBUSTKIQQH-UHFFFAOYSA-K lanthanum(3+);triacetate Chemical compound [La+3].CC([O-])=O.CC([O-])=O.CC([O-])=O JLRJWBUSTKIQQH-UHFFFAOYSA-K 0.000 description 1
- FYDKNKUEBJQCCN-UHFFFAOYSA-N lanthanum(3+);trinitrate Chemical compound [La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O FYDKNKUEBJQCCN-UHFFFAOYSA-N 0.000 description 1
- VQEHIYWBGOJJDM-UHFFFAOYSA-H lanthanum(3+);trisulfate Chemical compound [La+3].[La+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O VQEHIYWBGOJJDM-UHFFFAOYSA-H 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- OKJMLYFJRFYBPS-UHFFFAOYSA-J tetraazanium;cerium(4+);tetrasulfate Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[Ce+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OKJMLYFJRFYBPS-UHFFFAOYSA-J 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- TYIZUJNEZNBXRS-UHFFFAOYSA-K trifluorogadolinium Chemical compound F[Gd](F)F TYIZUJNEZNBXRS-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20218668U DE20218668U1 (de) | 2002-12-03 | 2002-12-03 | Rezepturen für Zementzubereitungen als Knochenersatz |
| PCT/US2003/038580 WO2004050131A1 (en) | 2002-12-03 | 2003-12-03 | Formulation for a cement preparation as bone substitute |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524058A JP2006524058A (ja) | 2006-10-26 |
| JP2006524058A5 true JP2006524058A5 (cg-RX-API-DMAC7.html) | 2006-12-07 |
Family
ID=7977548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004557582A Pending JP2006524058A (ja) | 2002-12-03 | 2003-12-03 | 骨代用物としてのセメント調製物のための処方物 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1560609A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006524058A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050084094A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100540068C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003302607A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE20218668U1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004050131A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10032220A1 (de) | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium-ammonium-phosphat-Zemente, deren Herstellung und Verwendung |
| US7273523B2 (en) | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
| DE20218668U1 (de) * | 2002-12-03 | 2003-03-06 | Sanatis GmbH, 61191 Rosbach | Rezepturen für Zementzubereitungen als Knochenersatz |
| DE10340800A1 (de) * | 2002-12-20 | 2004-07-01 | Merck Patent Gmbh | Funktionalisierung unreaktiver Substrate |
| US7306786B2 (en) * | 2003-07-28 | 2007-12-11 | Skeletal Kinetics, Llc | Calcium phosphate cements comprising a water-soluble contrast agent |
| ES2396133T3 (es) | 2004-04-27 | 2013-02-19 | Kyphon SÀRl | Composiciones de sustitución osea y método de uso |
| US20050257714A1 (en) * | 2004-05-20 | 2005-11-24 | Constantz Brent R | Orthopedic cements comprising a barium apatite contrast agent |
| US7651701B2 (en) | 2005-08-29 | 2010-01-26 | Sanatis Gmbh | Bone cement composition and method of making the same |
| US7754005B2 (en) | 2006-05-02 | 2010-07-13 | Kyphon Sarl | Bone cement compositions comprising an indicator agent and related methods thereof |
| GB2442000A (en) * | 2006-06-07 | 2008-03-26 | Apatech Ltd | Biomedical materials containing gadolinium |
| US7507286B2 (en) | 2006-06-08 | 2009-03-24 | Sanatis Gmbh | Self-foaming cement for void filling and/or delivery systems |
| WO2008023462A1 (en) * | 2006-08-21 | 2008-02-28 | Next21 K.K. | Bone model, bone filler and process for producing bone filler |
| DE102007052116B4 (de) * | 2007-10-22 | 2013-02-21 | Heraeus Medical Gmbh | Einkomponenten-Knochenzementpasten, deren Verwendung und Verfahren zu deren Aushärtung |
| DE102008010210A1 (de) * | 2008-02-20 | 2009-08-27 | Innotere Gmbh | Zubereitung für Magnesiumammoniumphosphat-Zemente |
| US9314545B2 (en) * | 2008-04-15 | 2016-04-19 | Life Science Enterprises, Inc. | Minimally invasive treatment of vertebra (MITV) using a calcium phosphate combination bone cement |
| US7968616B2 (en) | 2008-04-22 | 2011-06-28 | Kyphon Sarl | Bone cement composition and method |
| US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
| KR101357673B1 (ko) * | 2012-09-03 | 2014-02-04 | 한국기계연구원 | 인산 마그네슘을 포함하는 경조직 재생용 지지체 조성물, 이를 포함하는 경조직 재생용 지지체 및 이들의 제조방법 |
| CA2901528C (en) | 2013-02-20 | 2022-07-26 | Bone Support Ab | Heat-treated, sintered and micronized hydroxyapatite powder for use in a hardenable bone substitute composition |
| WO2016137013A1 (ja) * | 2015-02-26 | 2016-09-01 | 国立大学法人北海道大学 | 放射線治療用の病変識別マーカーおよび放射線治療用の病変識別マーカーキット |
| US20190201557A1 (en) * | 2016-08-25 | 2019-07-04 | National University Corporation Hokkaido University | Lesion identification marker utilizing bone cement for use in radiation therapy, and lesion identification marker kit for use in radiation therapy |
| RU2643337C1 (ru) * | 2017-06-06 | 2018-01-31 | Федеральное государственное бюджетное учреждение науки Институт химии Дальневосточного отделения Российской академии наук (ИХ ДВО РАН) | Резорбируемый рентгеноконтрастный кальций-фосфатный цемент для костной пластики |
| AU2021309336A1 (en) * | 2020-07-17 | 2023-02-16 | Zetagen Therapeutics, Inc. | Methods and compositions to graft bone using iron excipients |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03174349A (ja) * | 1989-12-01 | 1991-07-29 | Mitsubishi Materials Corp | 水硬性リン酸カルシウムセメント |
| JPH04329961A (ja) * | 1991-05-01 | 1992-11-18 | Onoda Cement Co Ltd | 医科用または歯科用硬化性組成物 |
| EP0511868B1 (en) * | 1991-05-01 | 1996-09-25 | Chichibu Onoda Cement Corporation | Medical or dental hardening compositions |
| JP3000718B2 (ja) * | 1991-05-28 | 2000-01-17 | 三菱マテリアル株式会社 | 薬物徐放性リン酸カルシウムセメント |
| DE69205736T2 (de) * | 1991-06-26 | 1996-06-13 | Nitta Gelatin Kk | Härtbares kalziumphosphathaltiges Material zum Reparieren von lebenden Hartgeweben. |
| JPH0734816B2 (ja) * | 1991-06-26 | 1995-04-19 | 新田ゼラチン株式会社 | 医科用および歯科用硬化性材料 |
| JPH078548A (ja) * | 1993-06-24 | 1995-01-13 | Mitsui Toatsu Chem Inc | 硬化性生体用粉材 |
| JPH078550A (ja) * | 1993-06-28 | 1995-01-13 | Mitsuo Kondo | 医療用リン酸カルシウム |
| US6075067A (en) * | 1994-08-15 | 2000-06-13 | Corpipharm Gmbh & Co | Cement for medical use, method for producing the cement, and use of the cement |
| US6309420B1 (en) * | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
| JP4215884B2 (ja) * | 1998-03-23 | 2009-01-28 | 日本特殊陶業株式会社 | リン酸カルシウムセメント及びリン酸カルシウムセメント組成物 |
| US6593394B1 (en) * | 2000-01-03 | 2003-07-15 | Prosperous Kingdom Limited | Bioactive and osteoporotic bone cement |
| JP2001218774A (ja) * | 2000-02-10 | 2001-08-14 | Ngk Spark Plug Co Ltd | リン酸カルシウム系セメント用混練器具及びそれを用いたリン酸カルシウム系セメントの調製方法 |
| DE10032220A1 (de) * | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium-ammonium-phosphat-Zemente, deren Herstellung und Verwendung |
| JP2004511320A (ja) * | 2000-10-16 | 2004-04-15 | ユニバーシテイ・オブ・サウス・カロライナ | 反応性リン酸カルシウムナノ粒子を含む生体適合性セメント並びに前記セメントの製造及び使用方法 |
| DE20218668U1 (de) * | 2002-12-03 | 2003-03-06 | Sanatis GmbH, 61191 Rosbach | Rezepturen für Zementzubereitungen als Knochenersatz |
-
2002
- 2002-12-03 DE DE20218668U patent/DE20218668U1/de not_active Expired - Lifetime
-
2003
- 2003-12-03 AU AU2003302607A patent/AU2003302607A1/en not_active Abandoned
- 2003-12-03 JP JP2004557582A patent/JP2006524058A/ja active Pending
- 2003-12-03 KR KR1020057009928A patent/KR20050084094A/ko not_active Ceased
- 2003-12-03 WO PCT/US2003/038580 patent/WO2004050131A1/en not_active Ceased
- 2003-12-03 CN CNB2003801049195A patent/CN100540068C/zh not_active Expired - Fee Related
- 2003-12-03 EP EP03808436A patent/EP1560609A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050287071A1 (en) | Formulation for a cement preparation as bone substitute | |
| JP2006524058A (ja) | 骨代用物としてのセメント調製物のための処方物 | |
| EP1601387B1 (en) | A new bone substitute composition | |
| KR101565591B1 (ko) | 골 재흡수 억제제 방출용 주사형 인산칼슘 시멘트 | |
| JP6220350B2 (ja) | 注射用の生分解性骨セメントとそれを作製及び使用する方法 | |
| JP5307547B2 (ja) | 骨修復のための２相セメント前駆体系 | |
| US20070233213A1 (en) | Method of therapeutic treatment using a biocompatible ceramic composition | |
| JP2005537821A (ja) | 外科用のリン酸カルシウムをベースとする水硬性セメント | |
| US20050257714A1 (en) | Orthopedic cements comprising a barium apatite contrast agent | |
| JPH10248915A (ja) | リン酸カルシウムセメント硬化液及びリン酸カルシウムセメント硬化体用組成物 | |
| HK1097778B (en) | Cement formulation, bone substitute material and a process for the formation of cement preparation | |
| JP2626811B2 (ja) | 硬化性糊剤根管充填材 | |
| JP3423951B2 (ja) | リン酸カルシウム系硬化体用粉剤 | |
| Mellier et al. | Gallium-doped calcium phosphates as a new approach for the local delivery of antiresorptive species | |
| JPH1111997A (ja) | リン酸カルシウムセメント及びリン酸カルシウムセメント硬化体の製造方法 | |
| HK1079464B (en) | A new bone substitute composition | |
| HK1051676B (en) | Magnesium-ammonium-phosphate cemente preparation, the production of the same and the use thereof, and the production on the cement |